Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesPharvaris BV

Pharvaris BV

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
34.47 USD 0.08 ( 0.23%)
Last update at 2026-11-09T21:00:00Z
VOLUME
633091
Market Cap
2671.98M

Momentum Score

…

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
34.09
Low
35.47
High
52 Week Price Range
20.65
Low
43.25
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
34.39
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-70.46%
Net Debt
-290.90M
ROCE
-63.90%
Diluted EPS TTM
-2.95

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -173.71M -132.40M -97.78M -75.65M -42.66M
Net income -175.70M -134.22M -98.81M -76.33M -42.73M
Selling general administrative 45.34M 46.72M 31.14M 29.34M 18.35M
Selling and marketing expenses - 0.40M 30.41M - -
Gross profit - - -0.25M -0.15M -0.08M
Reconciled depreciation 0.42M 0.27M 0.24M 0.15M 0.08M
Ebit -173.71M -145.69M -94.93M -86.74M -65.90M
Ebitda -173.29M -145.59M -94.67M -86.58M -65.82M
Depreciation and amortization 0.42M 0.10M 0.25M 0.15M 0.08M
Operating income -169.82M -145.69M -94.93M -86.74M -65.90M
Other operating expenses 169.82M 145.69M 94.93M 86.71M 54.14M
Interest expense - - 0.02M 0.02M 0.28M
Tax provision 1.99M 1.83M 0.60M 0.68M 0.07M
Net interest income 6.36M 5.42M 0.21M -0.04M -0.28M
Income tax expense 1.99M 1.83M 1.03M 0.68M 0.07M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 169.82M 145.69M 94.67M 86.71M 54.14M
Cost of revenue - - 0.25M 0.15M 0.08M
Total other income expense net -3.89M 13.29M -2.85M 11.08M 23.24M
Net income from continuing ops -175.70M -134.22M -107.32M -76.33M -42.73M
Net income applicable to common shares - - - -76.33M -42.73M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 301.45M 291.37M 399.02M 167.73M 212.09M
Other current assets 2.94M 5.75M 5.59M 0.58M 0.01M
Total liab 30.18M 23.61M 14.66M 18.47M 7.14M
Total stockholder equity 271.27M 267.76M 384.37M 149.26M 204.95M
Other current liab 23.35M 17.59M 11.08M 12.06M 4.76M
Common stock 7.83M 6.53M 6.28M 4.06M 3.98M
Capital stock 7.83M 6.53M 6.27M 4.06M 3.98M
Retained earnings -579.60M -402.26M -266.14M -164.19M -87.57M
Other assets - - - 0.26M -0.00M
Cash 291.68M 280.73M 391.55M 161.84M 209.35M
Total current liabilities 29.60M 22.97M 14.61M 18.22M 6.99M
Current deferred revenue - - 0.43M - -
Net debt -290.90M -279.87M -391.32M -161.40M -209.10M
Short term debt 0.20M 0.22M 0.20M 0.19M 0.10M
Short long term debt total 0.78M 0.86M 0.24M 0.44M 0.25M
Other stockholder equity 792.55M 623.64M 616.32M 289.18M 278.74M
Property plant equipment - - - 0.63M 0.35M
Total current assets 299.17M 289.42M 398.18M 166.85M 211.57M
Net tangible assets - - - 149.26M 204.95M
Net receivables 4.55M 2.94M 1.04M 0.38M 0.70M
Inventory - - 0.00M 4.04M 1.51M
Accounts payable 5.11M 4.56M 2.91M 5.98M 2.13M
Accumulated other comprehensive income 50.50M 39.85M 27.90M 20.21M 9.80M
Non currrent assets other - - 0.00M - -
Non current assets total 2.29M 1.96M 0.84M 0.89M 0.52M
Capital lease obligations 0.78M 0.86M 0.24M 0.44M 0.25M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.54M -0.09M -0.12M -0.13M
Change to liabilities - - - 3.91M 1.66M
Total cashflows from investing activities -0.16M -0.54M - -0.12M -0.13M
Net borrowings -0.22M -0.16M - -0.12M -0.12M
Total cash from financing activities 160.61M 2.68M 318.72M 8.65M 143.67M
Change to operating activities - - - 4.15M 0.04M
Net income -173.71M -132.40M -98.81M -75.65M -42.66M
Change in cash 10.95M -110.50M 230.17M -47.52M 110.72M
Begin period cash flow 280.73M 391.23M 161.38M 209.35M 98.63M
End period cash flow 291.68M 280.73M 391.55M 161.84M 209.35M
Total cash from operating activities -137.07M -120.13M -91.14M -67.16M -44.60M
Issuance of capital stock 171.74M 2.24M 64.20M 9.61M 156.83M
Depreciation 0.42M 0.27M 0.25M 0.15M 0.08M
Change to inventory - - -0.00M 0.15M -0.06M
Change to account receivables -0.33M -0.03M -0.04M 0.31M -0.14M
Other cashflows from financing activities -10.91M 0.59M -17.30M -0.84M -13.15M
Change to netincome - - - 0.64M -3.52M
Capital expenditures 0.16M 0.54M 0.09M 0.12M 0.13M
Change in working capital 7.62M 5.89M -5.74M 8.38M 1.58M
Stock based compensation 19.05M 16.21M 10.66M 11.35M 8.20M
Other non cash items 9.54M -10.10M 17.79M -11.39M 0.27M
Free cash flow -137.24M -120.67M -91.23M -67.29M -44.73M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
PHVS
Pharvaris BV		 0.08
0.23%		 34.47 - - - 7.82 -1.38
NVO
Novo Nordisk A/S		 1.09
2.72%		 41.41 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.78
0.69%		 550.87 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 15.61
1.73%		 919.96 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Pharvaris BV

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Grafenauweg 8, Zug, Switzerland, 6300

31 712036410

https://pharvaris.com

148

Name Title Year Born
Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA Co-Founder, CEO & Exec. Director 1959
Ms. Anna Nijdam M.Sc., R.A. Head of Fin. & Principal Accounting Officer 1981
Dr. Jochen Knolle Ph.D. Chief Scientific Officer & COO 1950
Ms. Joan Schmidt J.D. Chief Legal Officer 1964
Maryann Cimino Director of Corp. Relations NA
Ms. Annick Deschoolmeester Chief HR Officer NA
Dr. Peng Lu M.D., Ph.D. Chief Medical Officer 1978
Dr. Anne Lesage Ph.D. Chief Early Devel. Officer 1961
Dr. Morgan Conn Ph.D. Chief Bus. Officer 1969
Mr. Wim Souverijns Ph.D. Chief Community Engagement & Commercial Officer 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…